

Francesco Giuseppe Foschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11364449/publications.pdf>

Version: 2024-02-01

58
papers

2,713
citations

270111

25
h-index

206121

51
g-index

59
all docs

59
docs citations

59
times ranked

4494
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	6.1	57
2	Surveillance for hepatocellular carcinoma with a 3-months interval in â€œextremely high-riskâ€•patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.4	4
3	Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2022, 275, 743-752.	2.1	24
4	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507.	1.3	5
5	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.4	3
6	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	1.9	10
7	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	4.2	6
8	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021, 13, 592.	1.7	5
9	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	1.7	9
10	External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 520.	1.0	15
11	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021, 36, 54-61.	0.7	8
12	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	1.7	18
13	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021, 13, 2677.	1.7	6
14	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	1.9	18
15	Recalibrating survival prediction among patients receiving transâ€•arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	0.2	2
16	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.4	7
17	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. <i>Cancer Management and Research</i> , 2021, Volume 13, 9379-9389.	0.9	31
18	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	3.2	13
20	Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1177.	1.0	15
21	Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?. <i>Annals of Hepatology</i> , 2020, 19, 380-387.	0.6	19
22	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Cancers</i> , 2019, 11, 1023.	1.7	23
23	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. <i>Journal of Hepatology</i> , 2019, 71, 1175-1183.	1.8	64
24	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. <i>Gastrointestinal Tumors</i> , 2019, 6, 92-107.	0.3	22
25	<p>Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2981-2988.	1.0	26
26	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	1.9	41
27	Role of SIRT-3, p-mTOR and HIF-1 α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1503.	1.8	24
28	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , 2019, 6, 71-80.	0.3	4
29	Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e76-e78.	0.7	7
30	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 681-688.	0.4	49
31	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	0.9	38
32	Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. <i>European Radiology</i> , 2018, 28, 506-513.	2.3	63
33	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 403-414.	1.2	45
34	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018, 67, 1784-1796.	3.6	93
35	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. <i>BMC Gastroenterology</i> , 2018, 18, 177.	0.8	23
36	Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6555-6567.	1.0	30

#	ARTICLE	IF	CITATIONS
37	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	0.6	14
38	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	3.6	26
39	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.4	41
40	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 65-71.	1.8	83
41	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. <i>Scientific Reports</i> , 2017, 7, 42499.	1.6	30
42	Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1872-1880.	1.1	13
43	Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials. <i>Digestive and Liver Disease</i> , 2017, 49, 943-944.	0.4	14
44	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , 2017, 86, 106-114.	1.3	76
45	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 795-803.	1.7	23
46	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017, 37, 259-270.	1.9	67
47	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , 2017, 8, 66699-66708.	0.8	11
48	Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholic fatty liver disease: An Italian community-based population study. <i>Digestive and Liver Disease</i> , 2016, 48, 1357-1363.	0.4	22
49	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2016, 65, 727-733.	1.8	768
50	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002006.	3.9	113
51	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. <i>Oncotarget</i> , 2016, 7, 67142-67149.	0.8	91
52	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. <i>Oncotarget</i> , 2016, 7, 15243-15251.	0.8	26
53	eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. <i>Oncotarget</i> , 2016, 7, 27988-27999.	0.8	30
54	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015, 21, 1250-1258.	1.3	10

#	ARTICLE	IF	CITATIONS
55	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	1.8	184
56	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2719-2725.	0.9	66
57	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 333-341.	1.8	110
58	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. <i>Cancer</i> , 2014, 120, 2150-2157.	2.0	56